Try our Advanced Search for more refined results
IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION
Case Number:
2:13-md-02445
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Berger Montague
- Brown Moskowitz
- Burke LLP
- Clark Hill
- Cohen Milstein
- Cozen O'Connor
- Dilworth Paxson
- Dugan Law Firm
- Faruqi & Faruqi
- Fisher & Phillips
- FrancoLaw PLLC
- Garwin Gerstein
- Hach Rose Schirripa
- Hagens Berman
- Heins Mills
- Hellmuth & Johnson
- Hilliard Shadowen
- Hogan Lovells
- Jones Day
- Kessler Topaz
- Latham & Watkins
- Lynn Lynn Blackman & Manitsky
- Miller Shah
- Motley Rice
- Odom & Des Roches
- O'neill Kellner
- Oved & Oved
- Pomerantz LLP
- Post & Schell
- Radice Law Firm
- Robbins Geller
- Scott&Scott
- Seeger Weiss
- Sheehey Furlong
- Shub Johns
- Spector Roseman
- Sperling Kenny
- Spiro Harrison
- Steptoe LLP
- Taus Cebulash
- Troutman
- Venable LLP
- Weitz & Luxenberg
- Welsh & Recker
- Wexler Boley
- Wilentz Goldman
- WilmerHale
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Aquestive Therapeutics Inc.
- Indivior PLC
- MonoSol LLC
- Reckitt Benckiser Group PLC
- Rochester Drug Cooperative Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
September 17, 2014
Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers
Reckitt Benckiser Group PLC's move to discontinue Suboxone tablets, in lieu of a new dissolving-film version of the opiate addiction treatment, presented no antitrust injury for classes of purchasers who claim they were denied generic alternatives, a Pennsylvania federal judge heard Wednesday.
- ← Previous
- 1
- 2
- 3
- 4
- 5
- Next →